Biosimilars

24
Nov
Debarments Continue - Lachman Blog

Debarments Continue – How Many and for What?

The process of debarment began after the generic drug scandal in the late 1980s and the FDA continues to use this process to preclude individuals from participating in a variety of activities, including drug development, manufacture, clinical studies in support of drug applications, and importing drugs into this country if they are have been convicted […]

Read More
04
Nov
More from AAM’s GRx+Biosims October Meeting - Lachman Blog

More from AAM’s GRx+Biosims October Meeting

On day two of AAM’s October meeting, a panel including Jim Polli, Ph.D., Professor at the University of Maryland, Anna Scwenderman, Ph.D., Professor at the University of Michigan College of Pharmacy, and Aaron Josephson, Senior Director at Teva Pharmaceuticals, discussed the International Generic and Biosimilar Medicines Association’s (IGBA) project update on Single Global Development for […]

Read More
31
Oct
Big yellow arrow opposite direction with white arrows on asphalt road

Changes for Biosimilar Product Approvals – A Flash from AAM Meeting

The AAM GRx+Biosims meeting was in progress when word came down that, within minutes, a new guidance document would be released by the FDA to outline conditions under which comparative efficacy studies (CES) may not be required for biosimilar applications.  The draft Guidance for Industry (here) is titled Scientific Considerations in Demonstrating Biosimilarity to a […]

Read More
30
Oct
FY 2026 Applications - Lachman Blog

If You Must Remit, You Can’t Submit = Big Problem for Industry

As we near the end of October 2025, the first month of new FY 2026, and as FDA appropriations languish in our dysfunctional Congress, the number of fee-paying submissions submitted to FDA so far in the new Fiscal Year 2026 = 0. That’s right nada, nil, zero, zilch, none. You can count the number on […]

Read More
13
Oct
Should FDA Make Drug Pricing Part of the Review and Approval Process - Lachman Blog

Should FDA Make Drug Pricing Part of the Review and Approval Process? I Don’t Think So

Secretary Kennedy has basically accused much of the FDA and other parts of the HHS organization of being corrupt. One of his stated goals was to root out corruption. However, he never explicitly defined what the corruption was or identified any individual accused of it. Instead, he spoke of the revolving door where FDA employees […]

Read More
25
Sep
Bill Introduced in Congress to Make Biosimilar Drug Products Interchangeable Upon Approval - Lachman Blog

Bill Introduced in Congress to Make Biosimilar Drug Products Interchangeable Upon Approval

The proposed legislation is welcomed by those in the biosimilar space and the FDA because for years the FDA has said that all biosimilar products, based on the current review and approval paradigm, should be considered interchangeable. The EU has adopted that position as well; however, this bill, if passed, will be the necessary legislative […]

Read More
03
Sep
Atm Facade Cash Withdrawel

AAM Releases Generic and Biosimilar Savings Report for 2024

According to the Association for Accessible Medicine (AAM) report (here), generic drugs represent 90% of all prescriptions filled (accounting for approximately 3.9 billion prescriptions) while accounting for only 12% ($98 billion) of the total drug spend in 2024.  Conversely, brand-name drugs accounted for only 10% of prescriptions (approximately 435 million prescriptions) yet accounted for 88% ($700 billion) of the […]

Read More
01
Aug
toy Monarch butterfly emerging from its chrysalis.

Protocol Design and Lifecycle Following the Draft ICH Stability Guidance

  As discussed in a recent Lachman blog Revised Q1 Draft Stability Document Issued by FDA, the draft guidance titled Q1 Stability Testing of Drug Substances is a consolidated revision of ICH Q1A(R2), Q1B, Q1C, Q1D, Q1E, and Q5C.  This draft guidance provides guidance on product categories, such as advanced therapy medicinal products, vaccines, and other […]

Read More
14
Jul
instrument medicine

Petition Filed Regarding Rational Expiration Dates of Medications

In combing through regulations.gov this morning, I found a July 7, 2025 petition (here) submitted by a physician citing concerns about “prematurely expiring drugs.”  His point is that many drugs likely would still meet all of the required specifications outlined in an application well past their labeled expiration dates, which could positively impact drug shortages and […]

Read More
1 … 3 4 5 … 16